Universal Redirection of Chimeric Antigen Receptor T Cells Against Solid Tumors via Tumor Cell Membrane-Inserting CAR Ligands
Invention type: Technology
/
Case number: #24270H
The present disclosure relates generally to technologies comprising engineered immune cells that express chimeric antigen receptors (CARs) that specifically bind to a membrane-inserting amphiphilic ligand. Also disclosed herein are methods and compositions for treating a tumor.
Researchers
Darrell J Irvine
/
Alexander Hostetler
/
Laura Chen
/
Angela Zhang
Technology Areas: Biotechnology: Synthetic Biology / Therapeutics: Cell Based Therapy
Impact Areas: Healthy Living
-
car cells targeting an inserted ligand
United States of America | Published application
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.